Early identification of <i>TP53</i> mutations and <i>TP53</i> allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point‐of‐care p53 immunohistochemistry
IHC is a useful biomarker for the early detection of TP53-mutant MDS or AML and for prediction of TP53 allelic state. The results suggest a role for IHC across global markets, especially in geographic areas with inaccessibility to NGS testing.
Authors
- Yiyu Xie (ORCID: https://orcid.org/0000-0002-8434-9474)
- Sri Nuvvula (ORCID: https://orcid.org/0009-0007-3154-8238)
- Shyam Ajay Patel (ORCID: https://orcid.org/0000-0002-8208-1902)
- Jan Černý (ORCID: https://orcid.org/0000-0002-6602-5505)
- Salwa Khedr (ORCID: https://orcid.org/0000-0002-7209-2085)
- Shaoguang Li (ORCID: https://orcid.org/0000-0002-8947-9614)
- William Selove (ORCID: https://orcid.org/0000-0002-2736-2912)
- Lloyd Hutchinson
- Jonathan M. Gerber (ORCID: https://orcid.org/0000-0003-0524-8630)
- Carmelina Gordon (ORCID: https://orcid.org/0000-0002-0049-2565)
- Bruce A. Woda
- Noah Littman (ORCID: https://orcid.org/0000-0003-0625-395X)
Institutions
- UMass Memorial Health Care (US)
- University of Massachusetts Chan Medical School (US)
- NYU Langone Health (US)
- UMass Memorial Medical Center (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-06-21
- DOI
- https://doi.org/10.1002/cncr.35950
- Citations
- 4
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 7.08